| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ:CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the company has reached target enrollment of 540 participants in the randomized, placebo-controlled Phase 2 ‘START' Study. A number of additional patients are in the final stages of screening and will be randomized if they meet all eligibility requirements. START will assess the safety and activity of zervimesine (CT1812) in participants with mild cognitive impairment (MCI) or early Alzheimer's disease. Topline results are expected after all participants have completed 18 months of treatment.
The START study was initiated shortly after Leqembi was granted accelerated approval in the US. Cognition and ACTC made the decision to allow people on stable background therapy with an approved monoclonal antibody therapy to participate. Approximately 15% of participants randomized into START were also receiving infusions of either Leqembi (lecanemab) or Kisunla (donanemab).
Posted In: CGTX
